Anti-metastatic Effect of Zuoguiwan on Breast Cancer Cells and Its Mechanisms of Action

ZOU Le-lan; LIU Hong-ning; LYU Hong; XU Huan-jun; ZHU Xiao-cui; ZHANG Zhou-miao; FU Jian-jiang

doi:10.13422/j.cnki.syfjx.2017230085

您当前的位置：

首页 >

文章列表页 >

Anti-metastatic Effect of Zuoguiwan on Breast Cancer Cells and Its Mechanisms of Action

更新时间：2024-01-04

- Anti-metastatic Effect of Zuoguiwan on Breast Cancer Cells and Its Mechanisms of Action
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 23, Pages: 85-90(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017230085
  CLC： R285.5
- Published：2017
- 稿件说明：
移动端阅览
ZOU Le-lan, LIU Hong-ning, LYU Hong, et al. Anti-metastatic Effect of Zuoguiwan on Breast Cancer Cells and Its Mechanisms of Action[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(23): 85-90.
DOI：

ZOU Le-lan, LIU Hong-ning, LYU Hong, et al. Anti-metastatic Effect of Zuoguiwan on Breast Cancer Cells and Its Mechanisms of Action[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(23): 85-90. DOI： 10.13422/j.cnki.syfjx.2017230085.

摘要

目的：观察左归丸的抗乳腺癌转移作用，探讨其作用机制。方法：采用股骨内注射法建立人乳腺癌细胞MDA-MB-231骨转移裸鼠模型，受试裸鼠随机分为空白组（蒸馏水），左归丸低、高剂量（21，42 g·kg-1）组。连续给药8周后，采用巢式聚合酶链式反应（PCR）检测裸鼠骨髓组织中人细胞角蛋白（ck19）基因的表达，确定肿瘤转移情况；采用Oris法，检测左归丸含药血清对乳腺癌细胞MDA-MB-231体外迁移能力的影响；采用重组基底膜侵袭法，观察左归丸含药血清的体外抗侵袭作用；采用Alexa Fluor488®标记的鬼笔环肽（Phalloidin）进行荧光染色，观察左归丸含药血清对乳腺癌细胞纤维型肌动蛋白（F-actin）聚合的影响；采用蛋白质印迹法（Western blot）检测左归丸含药血清对MDA-MB-231细胞甲状旁腺激素相关蛋白（PTHrP）和4型趋化因子受体（CXCR4）表达的影响。结果：与空白组比较，左归丸高、低剂量均可显著抑制小鼠骨髓组织中人ck19基因表达（P<0.01）。Oris迁移表明，左归丸含药血清可显著抑制转化生长因子-β（TGF-β）诱导的MDA-MB-231细胞迁移；重组基底膜侵袭实验显示，左归丸含药血清也可显著抑制乳腺癌细胞对重组基底膜的侵袭能力。给药组侵袭细胞数较空白组显著降低（P<0.01）。Phalloidin荧光染色结果显示，左归丸含药血清可显著抑制F-actin聚合，抑制F-actin聚合体的形成。Western blot结果表明，左归丸含药血清可显著抑制乳腺癌细胞PTHrP，CXCR4蛋白表达。结论：左归丸具有明显的抗乳腺癌骨转移作用，其机制与抑制肿瘤细胞PTHrP，CXCR4表达，从而直接抑制其体外运动活性相关。

Abstract

Objective: To investigate the anti-metastatic effect of Zuoguiwan and its mechanisms of action. Method: The bone marrow metastasis mode of nude mice was established by intra-femoral injection. The tumor-bearing mice were randomly divided into three groups:control group

low-dose Zuoguiwan (21 g·kg-1 per day) treatment group and high-dose Zuoguiwan (42 g·kg-1 per day) treatment group. After successive administration for 8 weeks

the expression of human ck19 gene was detected by nest polymerase chain reaction (PCR) assay to determine the metastatic foci of MDA-MB-231 cells in bone marrow. Oris migration assay was performed to determine the effect of Zuoguiwan-containing sera on the migration of MDA-MB-231 cells. Reconstituted basement membrane invasion assay was conducted to decide the effect of Zuoguiwan-containing sera on the invasion of MDA-MB-231 cells. F-actin polymerization was detected with Alexa Fluor® 488 phalloidin and fluorescence microscopy. The effect of Zuoguiwan-containing sera on parathyroid hormone-related protein (PTHrP) and C-X-C chemokine receptor type 4 (CXCR4) expressions in MDA-MB-231 was determined by Western blot assay. Result: Compared with control group

both low-dose Zuoguiwan group and high-dose Zuoguiwan group exhibited a significant suppression on the expression of ck19 gene in bone marrow of tumor-bearing mice (P<0.01). Data from Oris migratory assay showed that Zuoguiwan-containing sera inhibited transforming growth factor-beta (TGF-β)-induced migration in MDA-MB-231 cells significantly. It was also found that the invasive ability of MDA-MB-231 cells through reconstituted basement membrane was inhibited by Zuoguiwan-containing sera in reconstituted basement membrane invasion assay. The amount of invaded cells in Zuoguiwan-containing sera treatment groups was less than that in control group obviously (P<0.01). Data from fluorescence assay showed that Zuoguiwan-containing sera inhibited F-actin polymerization of breast cancer cells. It was also showed that Zuoguiwan-containing sera suppressed the expressions of PTHrP and CXCR4 in Western blot assay

significantly. Conclusion: Zuoguiwan has a significant anti-metastatic effect on breast cancer cells. Its mechanism of action is correlated with the suppression on motility of breast cancer cells

and the down-regulation of PTHrP and CXCR4 expressions.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Zuoguiwan in Inhibiting Osteoclast Activation Induced by Breast Cancer via Regulating p38 MAPK/ERK Signaling Pathway

Exploring Mechanism of Breast Cancer Prevention by Liuwei Dihuangwan， Erzhiwan and Zuoguiwan Based on Macrophage Phagocytosis

Effects of Zuogui Wan on Osteolytic Metastasis Induced by Breast Cancer Cells

Effect of Zuoguiwan on Development of Skin Barrier in Neonatal Rat Model of Congenital Kidney Deficiency Based on Intercellular Connections

Related Author

FU Jianjiang

MEI Yinlong

MA Junchao

ZHU Xiaocui

WANG Wei

LYU Hong

ZHENG Lixiang

CHEN Yishan

Related Institution

Jiangxi University of Chinese Medicine

Jiangxi Province Key Laboratory for Diagnosis， Treatment and Rehabilitation of Cancer in Chinese Medicine

Hubei Uiversity of Chinese Medicine

Hubei Shizhen Labaratory

Dongfang Hospital， Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰